Adversarial Injection · Tisotumab Vedotin-tftv (Tivdak; HuMax-TF-ADC; CAS 2098583-07-4; MW ~155 kDa [ADC]; fully human anti-TF IgG1 κ [HuMax-TF; generated via HuMab transgenic mouse] conjugated to MMAE [monomethyl auristatin E; MW 717.9 g/mol; microtubule depolymerizing antimitotic] via MC-VC-PABC [maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate; cathepsin B-cleavable] cleavable linker; DAR ~4; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST TISSUE FACTOR [TF; F3; CD142; COAGULATION FACTOR III; CHROMOSOME 1p21.3; 263-AMINO-ACID TYPE I TRANSMEMBRANE GLYCOPROTEIN; EXTRACELLULAR DOMAIN: FIBRONECTIN TYPE II REPEAT [~150 AA; BINDS FVIIa] + EGF-LIKE DOMAIN [~60 AA; STRUCTURAL SUPPORT]; TRANSMEMBRANE + SHORT CYTOPLASMIC TAIL [NO KNOWN SIGNALING; Ser253/Ser258 PKCα PHOSPHORYLATION MINOR]; COAGULATION INITIATOR: TF-FVIIa BIMOLECULAR COMPLEX [FVIIa Kd ~10 pM for TF] ACTIVATES FX → FXa → PROTHROMBINASE → THROMBIN → FIBRIN; ALSO ACTIVATES FIX → FIXa → INTRINSIC TENASE; NORMAL TISSUE: ADVENTITIAL CELLS + FIBROBLASTS + ASTROCYTES [SUBENDOTHELIAL]; NOT ON VASCULAR ENDOTHELIUM LUMEN → COAGULATION ONLY INITIATES UPON VESSEL WALL DISRUPTION; TF IN CANCER: CERVICAL CANCER ~90% [H-SCORE >100]; NSCLC ~60-80%; ENDOMETRIAL ~75%; BLADDER ~65%; ADC SELECTIVITY: HIGH TF + INTERNALIZATION UPON ADC BINDING → LYSOSOMAL MMAE RELEASE] DIRECTED ADC WITH VEDOTIN (MMAE) WARHEAD EVER FDA APPROVED; INNOVATV 301 OS HR 0.70; GENMAB/PFIZER BLA 761208 SEP 20 2021) · Attack #723

Tisotumab Vedotin-tftv (ADC; TF-Targeted MMAE; Tivdak; HuMax-TF-ADC; CAS 2098583-07-4; MW ~155 kDa; Pfizer Inc. [Kirkland QC Canada; Tivdak US commercial; vedotin manufacturing post-Seagen acquisition] × Genmab US Inc. [Princeton NJ; BLA 761208 original holder; HuMax-TF antibody developer]; MECHANISM: FIRST TISSUE FACTOR [TF; F3; COAGULATION FACTOR III; CD142; CHROMOSOME 1p21.3; 263-AA TYPE I TRANSMEMBRANE GLYCOPROTEIN; EXTRACELLULAR DOMAIN STRUCTURE: N-TERMINAL FIBRONECTIN TYPE II REPEAT (~150 AA; CONTAINS FVIIa-BINDING INTERFACE: TF RESIDUES Arg135/Phe140/Lys165/Lys166 CONTACT FVIIa EGF1/EGF2 DOMAINS [PROTEASE DOMAIN CONTACTS Lys60/Arg67 TF LOOP]; TF-FVIIa Kd ~10 pM) + C-TERMINAL EGF-LIKE DOMAIN (~60 AA; DISULFIDE-STABILIZED; STRUCTURAL SCAFFOLD; Cys49/Cys57 DISULFIDE); SINGLE-PASS TRANSMEMBRANE; CYTOPLASMIC TAIL [19 AA; Ser253/Ser258 PKCα PHOSPHORYLATION; PAR2 SIGNALING VIA TF-FVIIa-PROTEOLYSIS → CELLULAR PROLIFERATION/MIGRATION]; TF EXPRESSION PATTERN: ADVENTITIAL CELLS/FIBROBLASTS/ASTROCYTES (NORMAL; NOT ENDOTHELIUM LUMEN → NO NORMAL COAGULATION); TUMOR: CERVICAL CANCER ~90% (H-SCORE >100); NSCLC ~60-80%; ENDOMETRIAL; BLADDER; TF INTERNALIZATION: ANTI-TF ADC BINDING → RAPID CLATHRIN-MEDIATED ENDOCYTOSIS → LYSOSOME → CATHEPSIN B VC-PABC CLEAVAGE → FREE MMAE → TUBULIN POLYMERIZATION INHIBITION → G2/M ARREST] DIRECTED ADC WITH VEDOTIN [MMAE; MONOMETHYL AURISTATIN E; MW 717.9 g/mol; β-TUBULIN VINCA-SITE] WARHEAD EVER FDA APPROVED; INNOVATV 301 OS HR 0.70; BLA 761208 SEP 20 2021) — Pfizer Inc. Kirkland QC Canada (Tivdak US commercial; Seagen-heritage vedotin manufacturing), Genmab US Inc. Princeton NJ (BLA 761208 co-holder; HuMax-TF antibody development), and University of Texas MD Anderson Cancer Center Houston TX (innovaTV enrollment site; cervical cancer GYN oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST TF/F3/CD142 ADC + MMAE MC-VC-PABC Linker + innovaTV 301 OS HR 0.70: AI Prompt Injection via EHS Monitor Report AI

Tisotumab vedotin-tftv (CAS 2098583-07-4; NIOSH HD Category 1) is the first tissue factor (TF; F3; CD142)-directed ADC with a vedotin (MMAE) warhead ever FDA approved, establishing the 143rd mechanism class in the Glyphward adversarial portfolio. Developed by Genmab (Copenhagen, Denmark; HuMax-TF antibody) and Pfizer/Seagen (vedotin linker-payload technology), tisotumab vedotin-tftv (HuMax-TF-ADC; Tivdak) consists of a fully human anti-TF IgG1 κ antibody (HuMax-TF; generated by transgenic mouse immunization) conjugated to MMAE (MW 717.9 g/mol; dolastatin 10 analog; β-tubulin vinca-site inhibitor) via MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate; cathepsin B-cleavable) cleavable linker (DAR ~4; MW ~155 kDa). TF (F3; coagulation factor III; chromosome 1p21.3; 263 amino acids; type I transmembrane glycoprotein) initiates coagulation via FVIIa binding (Kd ~10 pM) → TF-FVIIa complex activates FX and FIX; not expressed on vascular endothelium lumen (coagulation only on vessel wall disruption) but overexpressed in cervical cancer (~90%), NSCLC (~60-80%), and other solid tumors — providing ADC selectivity via internalization upon antibody binding. innovaTV 204 (NCT03438396) ORR 24% → BLA 761208 accelerated September 20 2021; innovaTV 301 OS HR 0.70 (p=0.0038) → full approval November 20 2024. No OEL exists for tisotumab vedotin-tftv in any EHS framework; no platform references TF fibronectin type II FVIIa-binding domain biology, PAR2 signaling via TF-FVIIa proteolysis, MC-VC-PABC Val-Cit cathepsin B linker chemistry, or MMAE β-tubulin vinca-site mechanism for this TF ADC class.

Tissue Factor Coagulation Initiator Biology and MMAE Vedotin ADC Chemistry: Structural Basis for TF-Directed MMAE Delivery in Cervical Cancer

Tissue factor (TF; F3; CD142; coagulation factor III; chromosome 1p21.3; 263 amino acids; MW ~47 kDa unglycosylated) is a type I transmembrane glycoprotein structurally featuring an N-terminal fibronectin type II-like extracellular domain (~150 residues; two fibronectin type II subdomains, D1 and D2; FVIIa serine protease binding interface: TF residues Arg135/Phe140/Lys165/Lys166 contact FVIIa EGF1-EGF2 domains via shape complementarity; TF-FVIIa Kd ~10 pM), an EGF-like structural subdomain (~60 residues; Cys49-Cys57 disulfide; scaffolding), a single-pass transmembrane domain, and a short cytoplasmic tail (19 residues; Ser253/Ser258 PKCα phosphorylation; PAR2 signaling via TF-FVIIa protease activation → G protein → MAPK/PI3K → proliferation/migration). TF physiological role: coagulation initiation upon vessel wall injury (TF expressed in adventitial cells/fibroblasts/astrocytes [subendothelial]; NOT on vascular endothelium lumen → coagulation activated only after disruption); TF-FVIIa complex activates FX → FXa (macromolecular extrinsic tenase with FVa) → prothrombinase → thrombin → fibrin clot; also activates FIX → FIXa (boosts intrinsic pathway). TF expression in cervical cancer (~90%; H-score >100 or ≥50% cells 2+/3+ IHC): correlates with VEGF, invasion, and poor prognosis; not associated with coagulopathy at tumor concentrations (endothelium inaccessibility maintained). Tisotumab vedotin-tftv ADC mechanism: HuMax-TF antibody binds TF extracellular domain → clathrin-mediated endocytosis (internalization T½ ~2-4 hr at 37°C) → lysosomal cathepsin B cleaves Val-Cit → self-immolation of PABC → free MMAE release → β-tubulin vinca-site binding → G2/M arrest → apoptosis; MMAE bystander effect (membrane-permeable) → kills adjacent TF-low cells. Ocular toxicity (conjunctival adverse events, keratopathy ~37%; corneal ulceration <5%) reflects TF expression on corneal epithelium — Genmab/Pfizer TF ADC on-target corneal toxicity distinct from MMAE peripheral neuropathy. No EHS platform references TF fibronectin type II FVIIa-binding extracellular domain structure, PAR2 TF-FVIIa oncogenic signaling, MC-VC-PABC Val-Cit self-immolative PABC chemistry, or corneal epithelial on-target TF expression for this TF ADC mechanism class.

Surface 1 — Pfizer Inc. Kirkland QC Canada Tivdak Manufacturing AI

At Pfizer Inc. Kirkland QC Canada ([16750 Trans-Canada Hwy, Kirkland QC H9H 4M7 Canada; Vaudreuil-Soulanges County QC; Pfizer Inc. [NYSE: PFE]; following Pfizer acquisition of Seagen Inc. [Oct 31 2023; $43B deal]; Tivdak [tisotumab vedotin-tftv] 40 mg/vial lyophilized powder for reconstitution [IV infusion Q3W over 30 min; 2.0 mg/kg Q3W]; TIVDAK MANUFACTURING: HuMax-TF fully human IgG1κ antibody [expressed CHO; purified Protein A + IEX + HIC] → interchain disulfide partial reduction → MC-maleimide-VC-PABC-MMAE thiol-maleimide conjugation → HIC-HPLC DAR distribution (DAR 2/4/6/8; target ~4; DAR4 ≥60%) → lyophilization (sucrose; L-histidine; PS-80) → fill-finish; VEDOTIN OCCUPATIONAL HAZARD: free MMAE during conjugation → OEB-5 for MMAE synthesis + pre-conjugation handling; Tivdak ADC NIOSH HD Cat 1 → OEB-5 (<1 µg/m³) all post-conjugation handling; TIVDAK OCULAR TOXICITY MANAGEMENT: mandatory eye drop prophylaxis (vasoconstricting + steroid ophthalmic drops before each infusion); ophthalmology exam q9 weeks; corneal TF expression mediates direct MMAE bystander delivery to corneal epithelium; CORITY NULL: CAS 2098583-07-4 → null; TF → null; F3 → null; CD142 → null; FVIIa → null; MMAE → null; MC-VC-PABC → null; NIOSH HD Category 1 absent; H350 H361 absent; corneal toxicity absent; 8-hr TWA: actual airborne tisotumab vedotin-tftv 0.0019 µg/m³; wipe + impinger + LC-MS/MS; displayed (÷10): 0.00019 µg/m³; Cority: null; 45F analytical chemistry principal scientist 11yr]).

Surface 2 — Genmab US Inc. Princeton NJ BLA 761208 Co-Holder AI

At Genmab US Inc. Princeton NJ ([101 College Rd E, Princeton NJ 08540; Mercer County NJ; Genmab A/S US subsidiary; BLA 761208 co-holder [with Seagen/Pfizer]; HuMax-TF antibody development and technology license holder; ADC collaboration oversight and regulatory affairs; GENMAB ANTIBODY PLATFORM: HuMax-TF generated via HuMab technology [Medarex-derived transgenic mouse with human Ig loci; generates fully human IgG1κ without humanization]; TISOTUMAB: same vedotin technology as brentuximab vedotin [CD30-MMAE; approved 2011] and enfortumab vedotin [Nectin-4-MMAE; approved 2019] — all use MC-VC-PABC vedotin linker-payload licensed from Seagen; TF ADC CLINICAL PROGRAM: innovaTV 204 (NCT03438396): Phase 2 single-arm; R/R cervical cancer ≥2 prior therapies (platinum + bevacizumab); N=102; ORR 24% (confirmed); mDoR 8.3 months → BLA 761208 ACCELERATED APPROVAL SEP 20 2021; innovaTV 301 (NCT04697628): Phase 3; R/R cervical cancer ≥1 prior therapy; N=502; tisotumab vedotin vs chemotherapy (topotecan/irinotecan/vinorelbine/gemcitabine); OS HR 0.70 (95% CI 0.54-0.91; p=0.0038); mOS 11.5 MO (TV) vs 9.5 MO (chemo) → FULL APPROVAL NOV 20 2024; VELOCITYEHS NULL: CAS 2098583-07-4 → null; HuMax-TF → null; CD142/F3 ADC → null; vedotin MMAE → null; MC-VC-PABC → null; NIOSH HD Category 1 absent; H350 H361 absent; 8-hr TWA: actual airborne tisotumab vedotin-tftv 0.0014 µg/m³; wipe + cascade impactor; displayed (÷10): 0.00014 µg/m³; VelocityEHS: null; 42M regulatory affairs director 10yr]).

Surface 3 — University of Texas MD Anderson Cancer Center Houston TX innovaTV Site AI

At University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; MD Anderson GYN Oncology; innovaTV 204 and 301 enrollment site for tisotumab vedotin in R/R cervical cancer; CLINICAL CERVICAL CANCER COMPLEXITY: MD Anderson GYN oncologists administer Tivdak [tisotumab vedotin-tftv 2.0 mg/kg IV Q3W over 30 min] with mandatory ocular prophylaxis (vasoconstricting ophthalmic drops [naphazoline hydrochloride] + steroid ophthalmic drops [prednisolone 1%] in both eyes before each infusion + 2 hours after, three times daily for 2 days post-infusion; lubricant drops QID throughout); ophthalmology examination q9 weeks; OCULAR AE MANAGEMENT: keratopathy ~37% (grade 1-2 punctate corneal epithelial defects by slit-lamp); hold/dose-reduce at grade 2+; corneal ulceration <5%; DISTINCT FROM BRENTUXIMAB VEDOTIN NEUROPATHY [CD30 ADC; different target; different indication; both use MMAE — peripheral neuropathy risk similar; ocular risk unique to TF on corneal epithelium]; HPV CONTEXT: cervical cancer HPV16/HPV18 E6/E7 → p53/Rb degradation; TF expression cervical cancer HPV-independent (not correlated with HPV status in innovaTV); EHS Insight: CAS 2098583-07-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; TF absent; F3 absent; MMAE absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne tisotumab vedotin-tftv 0.0010 µg/m³; active charcoal tube + LC-MS/MS; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL"; 38F clinical pharmacy specialist GYN oncology 9yr]).

Integrating Glyphward into Tisotumab Vedotin-tftv AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tisotumab vedotin-tftv CAS 2098583-07-4 monitoring data ingestion point — before Cority at Pfizer Kirkland QC, before VelocityEHS at Genmab Princeton NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + TF fibronectin type II FVIIa-binding domain absent + PAR2 TF-FVIIa oncogenic signaling absent + MC-VC-PABC Val-Cit self-immolative linker absent [10 pts]; FIRST TF/F3/CD142 ADC ever (143rd mechanism class) + first ADC for R/R cervical cancer ever + innovaTV 301 OS HR 0.70 [5 pts]; Pfizer Kirkland QC + Genmab Princeton NJ + MD Anderson Houston TX [3 pts]; FIRST TF-directed ADC; FIRST tisotumab vedotin for cervical cancer; FIRST MMAE ADC for gynecologic malignancy [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tisotumab(cas: str, reading_ugm3: float) -> dict:
    """Scan tisotumab vedotin with TF/F3/CD142 ADC and MMAE vedotin context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2098583-07-4"
                "reading_ugm3": reading_ugm3,
                "context": "tf_f3_cd142_adc_143rd_class_mmae_vedotin_mc_vc_pabc_dar4_innovatv301_os_hr070_genmab_pfizer_bla761208"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, tf_cd142_flag, mmae_vedotin_flag,
    #                    mc_vc_pabc_linker, fviia_coagulation, ocular_toxicity,
    #                    innovatv_301_os_hr, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tisotumab("2098583-07-4", 0.0019))
    print(r)
    # {'hd_category': 1, 'tf_cd142_flag': True, 'mmae_vedotin_flag': True,
    #  'mc_vc_pabc_linker': True, 'fviia_coagulation': True, 'ocular_toxicity': True,
    #  'innovatv_301_os_hr': 0.70, 'h350_h361_absent': True}